Prediction o f D isease O utcome i n M elanoma P atients b y Molecular A nalysis o f P araffin-Embedde d S entinel Lymph N odes

Purpose: A significant number of patients who develop recurrence after a histopathologically negative sentinel lymph node (SLN) biopsy will demonstrate occult metastases on re-evaluation of the SLNs with serial sectioning and immunohistochemistry. Reverse transcriptase polymerase chain reaction (RT-PCR) has been evaluated to improve disease staging and avoid false-negative findings in fresh or frozen-section SLNs. The purpose of this study was to develop a multimarker RT-PCR assay for assessing melanoma patients’ archived paraffin-embedded (PE) SLNs. Patients and Methods: Archived PE histopathologically positive (n 37) and negative (n 40) SLNs from patients with primary melanoma were analyzed using a semiquantitative multimarker RT-PCR assay. Results: Marker expression in histopathologically positive and negative SLNs were as follows: 89%, 92%, 35%, and 43% (positive) and 40%, 33%, 5%, and 13% (negative) for tyrosinase, melanoma antigen recognized by T cells-1, tyrosinase-related protein-1, and tyrosinase-related protein-2, respectively. Twenty-five percent of histopathologically negative SLN patients were upstaged using at least two markers. Of these, 80% developed a recurrence. Furthermore, at a median follow-up of 55 months, patients with histopathologically negative SLNs who expressed zero or one marker had a significantly improved disease-free (P < .002) and overall (P < .03) survival versus those expressing two or more markers. Conclusion: These findings demonstrate the feasibility of a multimarker RT-PCR assay for evaluating archived PE SLNs. More significantly, identification of molecular risk factors can be detected in histopathologically negative SLNs for distinguishing early-stage melanoma patients with a worse prognosis. J Clin Oncol 21:3566-3572. © 2003 by American Society of Clinical Oncology.

[1]  M. Monden,et al.  Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Giuliano,et al.  Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. , 2001, Cancer research.

[3]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Hong Wang,et al.  Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. , 2001, The American journal of pathology.

[5]  R. Turner,et al.  Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Morton,et al.  The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[7]  M. Monden,et al.  Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  P B Cerrito,et al.  Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Lyman,et al.  Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. , 2000, Annals of surgery.

[10]  R. Elashoff,et al.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. , 2000, Cancer research.

[11]  C. Garbe,et al.  Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. , 2000, The Journal of investigative dermatology.

[12]  R. Elashoff,et al.  Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Cheney,et al.  Accuracy of Pathologic Techniques for the Diagnosis of Metastatic Melanoma in Sentinel Lymph Nodes , 1999, Annals of Surgical Oncology.

[14]  M. Mihm,et al.  Detection of microscopic melanoma metastases in sentinel lymph nodes , 1999, Cancer.

[15]  D. Reintgen,et al.  Pathologic examination of the sentinel lymph node in malignant melanoma. , 1999, The American journal of surgical pathology.

[16]  D. Coit,et al.  Detection of Tyrosinase mRNA by Reverse Transcription Polymerase Chain Reaction in Melanoma Sentinel Nodes , 1999, Annals of Surgical Oncology.

[17]  M. Mihm,et al.  Outcome of patients with melanoma and histologically negative sentinel lymph nodes. , 1999, Archives of surgery.

[18]  A. Giuliano,et al.  Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple‐marker RT‐PCR , 1998, International journal of cancer.

[19]  A. Giuliano,et al.  Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. , 1998, The cancer journal from Scientific American.

[20]  G. Lyman,et al.  Molecular staging of malignant melanoma: correlation with clinical outcome. , 1998, JAMA.

[21]  T. Ravikumar,et al.  Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. , 1998, Journal of the American College of Surgeons.

[22]  M. Ross,et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D J Reeder,et al.  Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. , 1998, Clinical chemistry.

[24]  G. Raj,et al.  Utilization of polymerase chain reaction technology in the detection of solid tumors , 1998, Cancer.

[25]  D. Garrison,et al.  Melanoma-associated antigens as messenger RNA detection markers for melanoma. , 1997, Cancer research.

[26]  J. G. van den Tweel,et al.  Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. , 1996, The American journal of pathology.

[27]  D. Morton,et al.  Detection of β‐human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma , 1996 .

[28]  Messina,et al.  Accurate Nodal Staging of Malignant Melanoma. , 1995, Cancer control : journal of the Moffitt Cancer Center.

[29]  M. Ross,et al.  The Orderly Progression of Melanoma Nodal Metastases , 1994, Annals of surgery.

[30]  Alice Chung,et al.  Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer , 1994, Annals of surgery.

[31]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[32]  A. Cochran,et al.  Occult Tumor Cells in the Lymph Nodes of Patients with Pathological Stage I Malignant Melanoma An Immunohistological Study , 1988, The American journal of surgical pathology.

[33]  A. Cochran,et al.  Occult melanoma in lymph nodes detected by antiserum to S‐100 protein , 1984, International journal of cancer.